GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ViroPharma, Inc. (FRA:VPH) » Definitions » Cyclically Adjusted FCF per Share

ViroPharma, (FRA:VPH) Cyclically Adjusted FCF per Share : €0.00 (As of Sep. 2013)


View and export this data going back to . Start your Free Trial

What is ViroPharma, Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ViroPharma,'s adjusted free cash flow per share for the three months ended in Sep. 2013 was €0.093. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €0.00 for the trailing ten years ended in Sep. 2013.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2024-09-23), ViroPharma,'s current stock price is €36.08. ViroPharma,'s Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2013 was €0.00. ViroPharma,'s Cyclically Adjusted Price-to-FCF of today is .


ViroPharma, Cyclically Adjusted FCF per Share Historical Data

The historical data trend for ViroPharma,'s Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViroPharma, Cyclically Adjusted FCF per Share Chart

ViroPharma, Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ViroPharma, Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ViroPharma,'s Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, ViroPharma,'s Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroPharma,'s Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ViroPharma,'s Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ViroPharma,'s Cyclically Adjusted Price-to-FCF falls into.



ViroPharma, Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ViroPharma,'s adjusted Free Cash Flow per Share data for the three months ended in Sep. 2013 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=0.093/98.7900*98.7900
=0.093

Current CPI (Sep. 2013) = 98.7900.

ViroPharma, Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
200312 -0.118 77.758 -0.150
200403 -0.389 79.066 -0.486
200406 -0.265 80.037 -0.327
200409 -0.204 80.121 -0.252
200412 0.183 80.290 0.225
200503 0.184 81.555 0.223
200506 0.160 82.062 0.193
200509 0.383 83.876 0.451
200512 0.123 83.032 0.146
200603 0.029 84.298 0.034
200606 0.219 85.606 0.253
200609 0.472 85.606 0.545
200612 0.242 85.142 0.281
200703 0.066 86.640 0.075
200706 0.323 87.906 0.363
200709 0.344 87.964 0.386
200712 0.254 88.616 0.283
200803 0.102 90.090 0.112
200806 0.277 92.320 0.296
200809 0.320 92.307 0.342
200812 0.003 88.697 0.003
200903 -0.099 89.744 -0.109
200906 0.199 91.003 0.216
200909 0.196 91.120 0.212
200912 0.377 91.111 0.409
201003 0.314 91.821 0.338
201006 0.480 91.962 0.516
201009 0.376 92.162 0.403
201012 0.462 92.474 0.494
201103 0.277 94.283 0.290
201106 0.222 95.235 0.230
201109 0.440 95.727 0.454
201112 0.441 95.213 0.458
201203 0.472 96.783 0.482
201206 0.244 96.819 0.249
201209 -0.008 97.633 -0.008
201212 -0.345 96.871 -0.352
201303 0.154 98.209 0.155
201306 -0.054 98.518 -0.054
201309 0.093 98.790 0.093

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


ViroPharma,  (FRA:VPH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ViroPharma, Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of ViroPharma,'s Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


ViroPharma, Business Description

Industry
Traded in Other Exchanges
N/A
Address
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.

ViroPharma, Headlines

No Headlines